Literature DB >> 18956258

Strategies targeting telomerase inhibition.

Huaping Chen1, Yuanyuan Li, Trygve O Tollefsbol.   

Abstract

Telomerase plays a pivotal role in cellular immortality and tumorigenesis. Its activity is normally not detectable in most somatic cells while it is reactivated in the vast majority of cancer cells. Therefore, inhibition of telomerase has been viewed as a promising anticancer approach due to its specificity for cancer cells. Studies so far have shown that telomerase inhibition can inhibit the proliferation of cancer cells or cause apoptosis while it has no effect on most normal cells. Strategies currently being applied to induce telomerase inhibition target virtually all of the major components of the ribonucleoprotein holoenzyme and related cell signal pathways that regulate its activity. These strategies include inhibition of telomerase through targeting at the telomerase reverse transcriptase (TERT) catalytic subunit, the telomerase RNA (TR) component, and associated proteins. Other strategies have been developed to target the proteins associated with telomerase at the telomeric ends of chromosomes such as tankyrase. The specific mechanisms that mediate those inhibition effects include small molecules, antisense RNA, and ribozymes. Although the beneficial evidence of telomerase inhibition is obvious, limitations of strategies remain to be resolved to increase the feasibility of clinical application. This analysis will summarize recent developments of strategies in telomerase inhibition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18956258      PMCID: PMC2628964          DOI: 10.1007/s12033-008-9117-9

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  26 in total

1.  Inhibition of human telomerase by 7-deaza-2'-deoxyguanosine nucleoside triphosphate analogs: potent inhibition by 6-thio-7-deaza-2'-deoxyguanosine 5'-triphosphate.

Authors:  T M Fletcher; B E Cathers; K S Ravikumar; B M Mamiya; S M Kerwin
Journal:  Bioorg Chem       Date:  2001-02       Impact factor: 5.275

Review 2.  Molecular mechanisms of action of antisense drugs.

Authors:  S T Crooke
Journal:  Biochim Biophys Acta       Date:  1999-12-10

Review 3.  Telomeres and telomerase: basic science implications for aging.

Authors:  A Ahmed; T Tollefsbol
Journal:  J Am Geriatr Soc       Date:  2001-08       Impact factor: 5.562

Review 4.  RNA interference: biology, mechanism, and applications.

Authors:  Neema Agrawal; P V N Dasaradhi; Asif Mohmmed; Pawan Malhotra; Raj K Bhatnagar; Sunil K Mukherjee
Journal:  Microbiol Mol Biol Rev       Date:  2003-12       Impact factor: 11.056

Review 5.  A survey of telomerase activity in human cancer.

Authors:  J W Shay; S Bacchetti
Journal:  Eur J Cancer       Date:  1997-04       Impact factor: 9.162

Review 6.  Analysis of telomerase activity and detection of its catalytic subunit, hTERT.

Authors:  Sabita N Saldanha; Lucy G Andrews; Trygve O Tollefsbol
Journal:  Anal Biochem       Date:  2003-04-01       Impact factor: 3.365

Review 7.  Telomeres, telomerase, and telomerase inhibition: clinical implications for cancer.

Authors:  Ali Ahmed; Trygve Tollefsbol
Journal:  J Am Geriatr Soc       Date:  2003-01       Impact factor: 5.562

8.  Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways.

Authors:  Tetsuzo Tauchi; Kazuo Shin-Ya; Goro Sashida; Masahiko Sumi; Akihiro Nakajima; Takashi Shimamoto; Junko H Ohyashiki; Kazuma Ohyashiki
Journal:  Oncogene       Date:  2003-08-14       Impact factor: 9.867

9.  Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells.

Authors:  Kai Kraemer; Susanne Fuessel; Uta Schmidt; Matthias Kotzsch; Bernd Schwenzer; Manfred P Wirth; Axel Meye
Journal:  Clin Cancer Res       Date:  2003-09-01       Impact factor: 12.531

10.  Screening of telomerase inhibitors.

Authors:  Elke Kleideiter; Kamilla Piotrowska; Ulrich Klotz
Journal:  Methods Mol Biol       Date:  2007
View more
  16 in total

1.  Telomeres and telomerase as novel drug targets: reflections on the 2009 Nobel Prize in Physiology or Medicine.

Authors:  Meng Dong; Thomas E Mürdter; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2009-11-21       Impact factor: 2.953

Review 2.  HSP90 manages the ends.

Authors:  Diane C DeZwaan; Brian C Freeman
Journal:  Trends Biochem Sci       Date:  2010-03-16       Impact factor: 13.807

3.  MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.

Authors:  Antonella Flacco; Vienna Ludovini; Fortunato Bianconi; Mark Ragusa; Guido Bellezza; Francesca R Tofanetti; Lorenza Pistola; Annamaria Siggillino; Jacopo Vannucci; Lucio Cagini; Angelo Sidoni; Francesco Puma; Marileila Varella-Garcia; Lucio Crinò
Journal:  Am J Clin Oncol       Date:  2015-04       Impact factor: 2.339

4.  Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation.

Authors:  Huaping Chen; Charles N Landen; Yuanyuan Li; Ronald D Alvarez; Trygve O Tollefsbol
Journal:  Exp Cell Res       Date:  2013-01-16       Impact factor: 3.905

5.  Cell senescence culturing methods.

Authors:  Huaping Chen; Yuanyuan Li; Trygve O Tollefsbol
Journal:  Methods Mol Biol       Date:  2013

Review 6.  Therapeutic Targets in Telomerase and Telomere Biology of Cancers.

Authors:  Rajendra Prasad; Deeksha Pal; Wajid Mohammad
Journal:  Indian J Clin Biochem       Date:  2020-03-10

7.  Regulation of telomerase alternative splicing: a target for chemotherapy.

Authors:  Mandy S Wong; Ling Chen; Christopher Foster; Radhika Kainthla; Jerry W Shay; Woodring E Wright
Journal:  Cell Rep       Date:  2013-04-04       Impact factor: 9.423

8.  In silico prediction of antimalarial drug target candidates.

Authors:  Philipp Ludin; Ben Woodcroft; Stuart A Ralph; Pascal Mäser
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-07-17       Impact factor: 4.077

9.  Telomerase reverse transcriptase inhibition stimulates cyclooxygenase 2 expression in cancer cells and synergizes with celecoxib to exert anti-cancer effects.

Authors:  T Liu; X Liang; B Li; M Björkholm; J Jia; D Xu
Journal:  Br J Cancer       Date:  2013-05-16       Impact factor: 7.640

10.  Enhancement of Cisplatin-Mediated Apoptosis in Ovarian Cancer Cells through Potentiating G2/M Arrest and p21 Upregulation by Combinatorial Epigallocatechin Gallate and Sulforaphane.

Authors:  Huaping Chen; Charles N Landen; Yuanyuan Li; Ronald D Alvarez; Trygve O Tollefsbol
Journal:  J Oncol       Date:  2013-02-17       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.